![](https://impilo.se/wp-content/uploads/2023/12/ravicti-340x260.webp)
Scantox acquires Timeline Bioresearch and Adlego Biomedical – strengthening its position as the leading Nordic provider of pre-clinical research services
Scantox A/S, the leading Nordic GLP-compliant pre-clinical contract research organization, headquartered in Denmark and since 2021 owned by Impilo, is pleased to announce the acquisitions of Swedish Timeline Bioresearch AB in Lund and Adlego Biomedical AB in Stockholm. Timeline Bioresearch and Adlego Biomedical possess leading capabilities in efficacy and explorative research services and bring highly complementary service offerings to Scantox’s stronghold in pharmacology and regulatory toxicology. Moreover, the acquisitions represent important first steps towards broadening the Company’s portfolio of services, to support its growing customer base earlier in the drug development process.
News
![](https://impilo.se/wp-content/uploads/2024/09/MiniGo_600x337_130324-315x300.png)
Impilo acquires Qufora in partnership with existing shareholders
Impilo is now the majority shareholder in the Danish medtech company Qufora, which produces clinical aids for patients with chronic bowel conditions. This partnership will enable Qufora to accelerate its international expansion.
![](https://impilo.se/wp-content/uploads/2024/04/ana-francisconi-1436548-unsplash-315x500.jpg)
KKR and Impilo announce strategic partnership together with management in rare disease platform Immedica Pharma
Stockholm and London, 23 April 2024 – Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.
![](https://impilo.se/wp-content/uploads/2024/02/cris-trung-3wK7RLRAAkA-unsplash_aviapharma_landingpage-qj7uiwo7cyjal8ag8kydvsn338wmo96z2gi19upjgw.jpeg-315x300.webp)
Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform
Impilo has closed its investment in Avia Pharma Holding AB, a Sweden-based OTC and Rx pharmaceutical company with presence in the Nordics and Germany. Impilo now partners with two of the co-founders and management of Avia. Our ambition is to build a leading Northern European OTC / Rx platform through organic and inorganic growth.